<DOC>
	<DOCNO>NCT00494663</DOCNO>
	<brief_summary>DiObex Inc. develop experimental drug ( DIO-902 ) make part ketoconazole molecule treatment elevate blood glucose associate type 2 diabetes mellitus . Ketoconazole ( Nizoral® ) drug available prescription treatment fungal infection however DIO-902 investigational drug . DIO-902 may lower blood glucose lowering level naturally occur hormone call cortisol . Elevated cortisol may contribute development type 2 diabetes . The purpose research study test safety DIO-902 take mouth metformin cholesterol-lowering drug atorvastatin determine type severity side effect treatment . Other purpose study see treatment affect blood glucose level , cholesterol level , blood pressure , waist circumference .</brief_summary>
	<brief_title>A Phase 2b Study DIO-902 DIO-902 Placebo Addition Metformin Atorvastatin Atorvastatin Placebo Type 2 Diabetes</brief_title>
	<detailed_description>DIO-902 may lower blood glucose lowering level naturally occur hormone call cortisol . Elevated cortisol may contribute development type 2 diabetes . Clinical trial ketoconazole carried patient type 2 diabetes . Three clinical trial DIO-902 complete 37 patient type 2 diabetes 42 normal healthy volunteer ( people without type 2 diabetes ) enrol . Patients study receive multiple dos DIO-902 . DIO-902 may reduce level cortisol blood therefore may provide good control blood glucose level . STUDY DRUG ASSIGNMENT You randomize , , give 1 4 chance receive either 150mg/day DIO-902 , 300mg/day DIO-902 , 450mg/day DIO-902 DIO-902 placebo 1 2 chance receive 10mg/day atorvastatin atorvastatin placebo . The study drug tablet take mouth water . You take 3 tablet DIO-902 DIO-902 placebo 1 tablet atorvastatin atorvastatin placebo day . The tablet take time day ( 2200h 10:00pm ) . Neither doctor know dose DIO-902 DIO-902 placebo whether take atorvastatin atorvastatin placebo . If necessary , doctor way find dose assign . Atorvastatin If take cholesterol-lowering drug , drug must discontinue day prior Pre-Treatment Visit ( Week -4 ) duration study . At Visit 1 ( Week 0 ) assign DIO-902 DIO-902 placebo either atorvastatin atorvastatin placebo . You continue take assign drug Study Visit 4 ( Week 8 ) . At Study Visit 4 ( Week 8 ) patient begin take atorvastatin remainder study . Your DIO-902 DIO-902 placebo assignment remain . Atorvastatin tablet supply Study Visit 6 ( Week 16 ) . At visit give prescription 28 day supply atorvastatin 10mg.day last Study Visit 7 ( Week 20 ) . There total 9 study visit . At visit follow occur : blood urine sample take , physical exam , assessment side effect , ECG perform .</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Metformin</mesh_term>
	<mesh_term>Atorvastatin Calcium</mesh_term>
	<mesh_term>Ketoconazole</mesh_term>
	<criteria>A subject may include study he/she meet follow criterion : 1 . Male female , age 18 75 2 . Females childbearing potential ( intact uterus within 1 year since last menstrual period ) nonlactating negative serum pregnancy test . In addition , subject agree use follow acceptable birth control method begin Screening Visit throughout study : 1. abstinence 2. surgical sterilization ( bilateral tubal ligation , hysterectomy , bilateral oophorectomy ) 6 month minimum 3 . IUD place least 3 month 4. barrier method ( condom diaphragm ) spermicide 5. surgical sterilization partner ( vasectomy 6 month ) 6. hormonal contraceptive least 3 month prior first dose 3 . Diagnosis type 2 diabetes mellitus ( DM ) least 6 month . 4 . Type 2 diabetes may treat metformin ( metformin hydrochloride tablet metformin hydrochloride extendedrelease tablet ) total daily dose 500 mg maximum label dose . ( See Appendix G List Drug Trade Names ) .The dose metformin must stable &gt; 8 week prior PreTreatment Visit ( Week 4 ) throughout course study . The subject must pharmacologic overthecounter treatment diabetes . 5 . HbA1C level 7.0 10.0 % 6 . Fasting Cpeptide level &gt; 0.33 nmol/l ( 1.0 ng/ml ) 7 . ACTH stimulation test result cortisol level &gt; 18 µg/dl baseline 60 minute 8 . Normal complete blood count ( CBC ) platelets differential 9 . 12lead electrocardiogram ( ECG ) show acute ischemia clinically significant abnormality . Subjects QTc interval &gt; 450 msec exclude study . 10 . BMI 27 42 kg/m2 ( see Appendix B ) 11 . Subjects history hypertension may stable antihypertensive regimen ( except drug state Exclusion Criterion 8 ) &gt; 6 week prior PreTreatment Visit ( Week 4 ) ) 12 . Ability comprehend willingness provide inform consent A subject may exclude study he/she meet follow criterion : 1 . Previous participation clinical trial DIO902 . 2 . History atherosclerotic disorder ( myocardial infarction , unstable angina , cerebrovascular accident , peripheral vascular disease congestive heart failure secondary ischemic myocardial injury ) would , estimation Investigator , make unsafe stop lipid lower drug 12 week course study . 3 . Known hypersensitivity idiosyncratic reaction relate ketoconazole imidazole compound . 4 . History malignancy ( except basal cell carcinoma ) within 3 year initial dose study medication . 5 . Excessive alcohol intake ( &gt; 20 g per day female ( 1.5 standard alcohol drink ) &gt; 30 g per day male ( 2.0 standard alcohol drink ) ( standard drink contain 14 g alcohol : 12 oz beer , 5 oz wine 1.5 oz spirit ) drug abuse . ( 1.0 fluid oz ( US ) = 29.57 ml ) 6 . Any clinically significant medical condition , determine Investigator . These clinically significant medical condition include , limited , uncontrolled hypertension , NYHA class III IV CHF , proliferative diabetic retinopathy neuropathic symptom limit activity daily live . 7 . Participation another clinical trial and/or treatment receive investigational agent within one month initial dose study medication . 8 . Concomitant therapy following : ( See Appendix G List Drug Trade Names ) 1. weight loss medication 2. oral inject hypoglycemics ( metformin allow ) insulin 3. oral , parenteral inhaled steroid ; nasal , topical ocular , intravitreal , low moderate potency topical steroid allow 4. dihydropyridine calcium channel blocker ( amlodipine , diltiazem verapamil allow ) 5 . H2 antagonists proton pump inhibitor ( liquid tablet antacid allow ) 6. midazolam , triazolam , alprazolam , terfenadine , astemizole , digoxin , coumarin derivative , phenytoin , rifampin , HIV protease inhibitor , spironolactone , aliskiren , erythromycin clarithromycin , cyclosporine tacrolimus 7 . Subjects currently take lipid lower medication may enrol Investigator determines subject condition preclude cessation lipid lower treatment 12 week . [ All subject require discontinue lipid lower therapy 4 week PreTreatment Period randomize receive either atorvastatin 10 mg atorvastatin placebo first 8 week Treatment Period . All subject receive atorvastatin 10 mg week 8 16 Treatment Period . ] Subjects may lipid lower agent Visit 7 ( Week 20 ) study . 9 . History HIV 10 . Positive hepatitis B ( HbsAg ) positive hepatitis C ( Hepatitis C antibody ) test Screening 11 . Liver function test must follow cutoff : ALT and/or AST &gt; 3.0X ULN , AP &gt; 1.5X ULN total bilirubin &gt; ULN . ( If LFTs WNL total bilirubin elevate , retest direct indirect bilirubin may perform . Subjects indirect total bilirubin 3X ULN ( presume Gilbert 's syndrome ) may enrol LFTs WNL . ) 12 . CK must &gt; 2.5X ULN clearly related recent exercise , injury unusual activity 13 . Creatinine must &gt; 1.4 mg/dl female &gt; 1.5 mg/dl male . 14 . Thyroid stimulate hormone level &gt; 1.5X ULN 15 . History lactic acidosis 16 . Known hypersensitivity cosyntropin ( ACTH ) component formulation ( mannitol sodium chloride ) 17 . Known intolerance statin drug 18 . Any condition increase risk participation trial opinion investigator</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>November 2008</verification_date>
	<keyword>diabetes</keyword>
	<keyword>type 2 diabetes</keyword>
	<keyword>cholesterol</keyword>
</DOC>